nach oben

Erschienen in:

10.12.2019 | Original Paper

Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study

verfasst von: Charlotte Skriver, Christian Dehlendorff, Michael Borre, Klaus Brasso, Signe Benzon Larsen, Anne Tjønneland, Anton Pottegård, Jesper Hallas, Henrik Toft Sørensen, Søren Friis

Erschienen in: Cancer Causes & Control | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Epidemiologic studies suggest that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce prostate cancer risk. We examined these associations overall and according to clinical and lifestyle parameters.

Methods

We identified male participants in the Danish Diet, Cancer and Health Study (n = 26,339), holding information on anthropometric measures and lifestyle factors. From Danish nationwide registries and medical records, we retrieved complete prescription histories and prostate cancer occurrence and characteristics. Cox regression was used to estimate hazard ratios (HRs) for prostate cancer associated with low-dose aspirin or nonaspirin NSAID use, overall and by clinical characteristics, anthropometric measures, and lifestyle factors.

Results

We identified 1,927 prostate cancer cases during a median follow-up of 17.0 years. Low-dose aspirin use was not associated with overall prostate cancer risk, but a reduced HR for nonaggressive prostate cancer (high use [≥ 1,825 tablets]: 0.79; 95% confidence interval (CI) 0.60–1.04) and an increased HR for aggressive disease (high use: 1.27; 95% CI 1.00–1.61) was observed with low-dose aspirin use. Long-term, high-intensity use (≥ 10 years with ≥ 0.25 defined daily doses/day) of nonaspirin NSAIDs was associated with an increased HR for prostate cancer (1.35, 95% CI 0.99–1.84), confined to localized and nonaggressive disease. No consistent variation in HRs was seen in analyses stratified by height, body mass index, smoking, and alcohol use.

Conclusion

Low-dose aspirin or other NSAID use was not associated with reduced prostate cancer risk, neither overall nor according to anthropometric measures, smoking, or alcohol use. The variation according to outcome characteristics warrants further investigation.

Nur mit Berechtigung zugänglich

Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, Ford LG, Jacobs EJ, Jankowski JA, La Vecchia C, Law M, Meyskens F, Rothwell PM, Senn HJ, Umar A (2015) Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 26:47–57. https://doi.org/10.1093/annonc/mdu225 CrossRefPubMed

Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, Lu Z (2018) Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer 18:288. https://doi.org/10.1186/s12885-018-4156-5 CrossRefPubMedPubMedCentral

Liu Y, Chen JQ, Xie L, Wang J, Li T, He Y, Gao Y, Qin X, Li S (2014) Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med 12:55. https://doi.org/10.1186/1741-7015-12-55 CrossRefPubMedPubMedCentral

Wang X, Lin YW, Wu J, Zhu Y, Xu XL, Xu X, Liang Z, Hu ZH, Li SQ, Zheng XY, Xie LP (2014) Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk. World J Surg Oncol 12:304. https://doi.org/10.1186/1477-7819-12-304 CrossRefPubMedPubMedCentral

Huang TB, Yan Y, Guo ZF, Zhang XL, Liu H, Geng J, Yao XD, Zheng JH (2014) Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol 46:1715–1728. https://doi.org/10.1007/s11255-014-0703-4 CrossRefPubMed

Shang Z, Wang X, Yan H, Cui B, Wang Q, Wu J, Cui X, Li J, Ou T, Yang K (2018) Intake of non-steroidal anti-inflammatory drugs and the risk of prostate cancer: a meta-analysis. Front Oncol 8:437. https://doi.org/10.3389/fonc.2018.00437 CrossRefPubMedPubMedCentral

Sauer CM, Myran DT, Costentin CE, Zwisler G, Safder T, Papatheodorou S, Mucci LA (2018) Effect of long term aspirin use on the incidence of prostate cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 132:66–75. https://doi.org/10.1016/j.critrevonc.2018.09.013 CrossRefPubMed

Drew DA, Cao Y, Chan AT (2016) Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 16:173–186. https://doi.org/10.1038/nrc.2016.4 CrossRefPubMedPubMedCentral

Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC, Morimoto T, Mehta Z (2018) Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 392:387–399. https://doi.org/10.1016/s0140-6736(18)31133-4 CrossRefPubMedPubMedCentral

10.

Wang X, Chan AT, Slattery ML, Chang-Claude J, Potter JD, Gallinger S, Caan B, Lampe JW, Newcomb PA, Zubair N, Hsu L, Schoen RE, Hoffmeister M, Brenner H, Le Marchand L, Peters U, White E (2018) Influence of smoking, body mass index, and other factors on the preventive effect of nonsteroidal anti-inflammatory drugs on colorectal cancer risk. Cancer Res 78:4790–4799. https://doi.org/10.1158/0008-5472.can-18-0326 CrossRefPubMedPubMedCentral

11.

Iyengar NM, Gucalp A, Dannenberg AJ, Hudis CA (2016) Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol 34:4270–4276. https://doi.org/10.1200/jco.2016.67.4283 CrossRefPubMedPubMedCentral

12.

Todoric J, Antonucci L, Karin M (2016) Targeting inflammation in cancer prevention and therapy. Cancer Prev Res 9:895–905. https://doi.org/10.1158/1940-6207.capr-16-0209 CrossRef

13.

Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL (2011) Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988–2006. Int J Cancer 128:2444–2452. https://doi.org/10.1002/ijc.25811 CrossRefPubMedPubMedCentral

14.

Tjønneland A, Olsen A, Boll K, Stripp C, Christensen J, Engholm G, Overvad K (2007) Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health 35:432–441. https://doi.org/10.1080/14034940601047986 CrossRefPubMed

15.

Gjerstorff ML (2011) The Danish Cancer Registry. Scand J Public Health 39:42–45. https://doi.org/10.1177/1403494810393562 CrossRefPubMed

16.

Pottegård A, Schmidt SA, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M (2017) Data resource profile: the Danish National Prescription Registry. Int J Epidemiol 46:798–798f. https://doi.org/10.1093/ije/dyw213 CrossRefPubMed

17.

Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490. https://doi.org/10.2147/clep.s91125 CrossRefPubMedPubMedCentral

18.

Baadsgaard M, Quitzau J (2011) Danish registers on personal income and transfer payments. Scand J Public Health 39:103–105. https://doi.org/10.1177/1403494811405098 CrossRefPubMed

19.

Schmidt M, Pedersen L, Sørensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29:541–549. https://doi.org/10.1007/s10654-014-9930-3 CrossRefPubMed

20.

Karlsen RV, Larsen SB, Christensen J, Brasso K, Friis S, Tjønneland A, Dalton SO (2013) PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study. Acta Oncol 52:1609–1614. https://doi.org/10.3109/0284186x.2013.831474 CrossRefPubMed

21.

WHO Collaborating Centre for Drug Statistics Methodology (2018) Guidelines for ATC classification and DDD assignment 2019. Oslo, Norway. https://www.whocc.no/filearchive/publications/2019_guidelines_web.pdf. Accessed 23 May 2019

22.

Pernar CH, Ebot EM, Wilson KM, Mucci LA (2018) The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a030361 CrossRefPubMed

23.

Campi R, Brookman-May SD, Subiela Henríquez JD, Akdoğan B, Brausi M, Klatte T, Langenhuijsen JF, Linares-Espinos E, Marszalek M, Roupret M, Stief CG, Volpe A, Minervini A, Rodriguez-Faba O (2018) Impact of metabolic diseases, drugs, and dietary factors on prostate cancer risk, recurrence, and survival: a systematic review by the European Association of Urology Section of Oncological Urology. Eur Urol Focus. https://doi.org/10.1016/j.euf.2018.04.001 CrossRefPubMed

24.

Pottegård A, Friis S, Stürmer T, Hallas J, Bahmanyar S (2018) Considerations for pharmacoepidemiological studies of drug–cancer associations. Basic Clin Pharmacol Toxicol 122:451–459. https://doi.org/10.1111/bcpt.12946 CrossRefPubMed

25.

Pottegård A, Hallas J (2016) New use of prescription drugs prior to a cancer diagnosis. Pharmacoepidemiol Drug Saf 26:223–227. https://doi.org/10.1002/pds.4145 CrossRefPubMedPubMedCentral

26.

Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509. https://doi.org/10.2307/2670170 CrossRef

27.

Ruan PK, Gray RJ (2008) Analyses of cumulative incidence functions via non-parametric multiple imputation. Stat Med 27:5709–5724. https://doi.org/10.1002/sim.3402 CrossRefPubMed

28.

Allignol A, Beyersmann J (2010) Software for fitting nonstandard proportional subdistribution hazards models. Biostatistics 11:674–675. https://doi.org/10.1093/biostatistics/kxq018 CrossRefPubMed

29.

R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/. Accessed 23 May 2019

30.

Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E (2010) Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomark Prev 19:3185–3188. https://doi.org/10.1158/1055-9965.EPI-10-0942 CrossRef

31.

Iqbal U, Yang HC, Jian WS, Yen Y, Li YJ (2017) Does aspirin use reduce the risk for cancer? J Investig Med 65:391–392. https://doi.org/10.1136/jim-2016-000275 CrossRefPubMed

32.

Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, Tonita J, Sharpe C, Aprikian AG (2011) Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS ONE 6:e16412. https://doi.org/10.1371/journal.pone.0016412 CrossRefPubMedPubMedCentral

33.

Tsoi KK, Ho JM, Chan FC, Sung JJ (2018) Long-term use of low-dose aspirin for cancer prevention: a 10-year population cohort study in Hong Kong. Int J Cancer. https://doi.org/10.1002/ijc.32083 CrossRef

34.

Hurwitz LM, Joshu CE, Barber JR, Prizment AE, Vitolins MZ, Jones MR, Folsom AR, Han M, Platz EA (2018) Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case-fatality in the atherosclerosis risk in communities study. Cancer Epidemiol Biomark Prev 28:563–569. https://doi.org/10.1158/1055-9965.epi-18-0965 CrossRef

35.

Kang M, Ku JH, Kwak C, Kim HH, Jeong CW (2018) Effects of aspirin, nonsteroidal anti-inflammatory drugs, statin, and COX2 inhibitor on the developments of urological malignancies: a population-based study with 10-year follow-up data in Korea. Cancer Res Treat 50:984–991. https://doi.org/10.4143/crt.2017.248 CrossRefPubMed

36.

Skriver C, Dehlendorff C, Borre M, Brasso K, Sørensen HT, Hallas J, Larsen SB, Tjønneland A, Friis S (2016) Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study. Cancer Causes Control 27:1067–1079. https://doi.org/10.1007/s10552-016-0785-7 CrossRefPubMed

37.

Nordström T, Clements M, Karlsson R, Adolfsson J, Grönberg H (2015) The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer 51:725–733. https://doi.org/10.1016/j.ejca.2015.02.003 CrossRefPubMed

38.

Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E (2006) Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 12:130–135PubMed

39.

Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R, Church TR, Chia D, Zhou C, Chu LW, Huang WY, Peters U, Kirsh VA, Chatterjee N, Leitzmann MF, Hayes RB, Hsing AW (2012) Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer 107:207–214. https://doi.org/10.1038/bjc.2012.227 CrossRefPubMedPubMedCentral

40.

Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ (2015) Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. Clin Cancer Res 21:756–762. https://doi.org/10.1158/1078-0432.ccr-14-2235 CrossRefPubMed

41.

Doat S, Cénée S, Trétarre B, Rebillard X, Lamy PJ, Bringer JP, Iborra F, Murez T, Sanchez M, Menegaux F (2017) Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. Cancer Med 6:2461–2470. https://doi.org/10.1002/cam4.1186 CrossRefPubMedPubMedCentral

42.

Ma Y, Brusselaers N (2018) Maintenance use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk. Prostate Cancer Prostatic Dis 21:147–152. https://doi.org/10.1038/s41391-017-0021-x CrossRefPubMed

43.

Veitonmäki T, Tammela TL, Auvinen A, Murtola TJ (2013) Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 49:938–945. https://doi.org/10.1016/j.ejca.2012.09.030 CrossRefPubMed

44.

Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A (2014) Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. Br J Cancer 111:1421–1431. https://doi.org/10.1038/bjc.2014.381 CrossRefPubMedPubMedCentral

45.

Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM (2018) The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol 15:11–24. https://doi.org/10.1038/nrurol.2017.167 CrossRefPubMed

46.

Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S (2015) Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 17:212. https://doi.org/10.1186/s13075-015-0728-9 CrossRefPubMedPubMedCentral

47.

Nguyen-Nielsen M, Borre M (2016) Diagnostic and therapeutic strategies for prostate cancer. Semin Nucl Med 46:484–490. https://doi.org/10.1053/j.semnuclmed.2016.07.002 CrossRefPubMed

48.

Schmidt M, Hallas J, Friis S (2014) Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999–2012. Clin Epidemiol 6:155–168. https://doi.org/10.2147/CLEP.S59156 CrossRefPubMedPubMedCentral

49.

Kalinowski A, Humphreys K (2016) Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. Addiction 111:1293–1298. https://doi.org/10.1111/add.13341 CrossRefPubMed

Titel: Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study
verfasst von: Charlotte Skriver
Christian Dehlendorff
Michael Borre
Klaus Brasso
Signe Benzon Larsen
Anne Tjønneland
Anton Pottegård
Jesper Hallas
Henrik Toft Sørensen
Søren Friis
Publikationsdatum: 10.12.2019
Verlag: Springer International Publishing
Erschienen in: Cancer Causes & Control / Ausgabe 2/2020
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-019-01252-5

Springer Medizin

Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study